clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Yamashita N et al. | Effects of antibacterial agents, levofloxacin and clarithromycin, on aquatic organisms. | 2006 | Water Sci. Technol. | pmid:16862775 |
| Sahar E et al. | Comparison of two treatments for the removal of selected organic micropollutants and bulk organic matter: conventional activated sludge followed by ultrafiltration versus membrane bioreactor. | 2011 | Water Sci. Technol. | pmid:21330721 |
| Lin AY et al. | Fate of selected pharmaceuticals and personal care products after secondary wastewater treatment processes in Taiwan. | 2010 | Water Sci. Technol. | pmid:21076233 |
| Ghosh GC et al. | Occurrence and elimination of antibiotics at four sewage treatment plants in Japan and their effects on bacterial ammonia oxidation. | 2009 | Water Sci. Technol. | pmid:19237773 |
| Harada A et al. | Biological effects of PPCPs on aquatic lives and evaluation of river waters affected by different wastewater treatment levels. | 2008 | Water Sci. Technol. | pmid:19001705 |
| Nakada N et al. | Occurrence of 70 pharmaceutical and personal care products in Tone River basin in Japan. | 2007 | Water Sci. Technol. | pmid:18075189 |
| Sein MM et al. | Oxidation of some typical wastewater contaminants (tributyltin, clarithromycin, metoprolol and diclofenac) by ozone. | 2009 | Water Sci. Technol. | pmid:19403960 |
| Nakada N et al. | Removal of selected pharmaceuticals and personal care products (PPCPs) and endocrine-disrupting chemicals (EDCs) during sand filtration and ozonation at a municipal sewage treatment plant. | 2007 | Water Res. | pmid:17632207 |
| Abegglen C et al. | The fate of selected micropollutants in a single-house MBR. | 2009 | Water Res. | pmid:19269669 |
| Vione D et al. | Phototransformation of selected human-used macrolides in surface water: kinetics, model predictions and degradation pathways. | 2009 | Water Res. | pmid:19249811 |
| Wang S et al. | Enhanced adsorption of ionizable antibiotics on activated carbon fiber under electrochemical assistance in continuous-flow modes. | 2018 | Water Res. | pmid:29426033 |
| Siemens J et al. | Concentrations and mobility of human pharmaceuticals in the world's largest wastewater irrigation system, Mexico City-Mezquital Valley. | 2008 | Water Res. | pmid:18083208 |
| Forrez I et al. | Biogenic metals for the oxidative and reductive removal of pharmaceuticals, biocides and iodinated contrast media in a polishing membrane bioreactor. | 2011 | Water Res. | pmid:21163512 |
| Yazdanbakhsh AR et al. | Reduction of non-Betalactam Antibiotics COD by Combined Coagulation and Advanced Oxidation Processes. | 2016 | Water Environ. Res. | pmid:28661328 |
| Vichev E et al. | [Gastroduodenitis and ulcers--statistical study for 1998]. | 2000 | Vutr Boles | pmid:11688321 |
| Starostin BD | [Modern means of anti-Helicobacter therapy]. | 2001 | Voen Med Zh | pmid:11764485 |
| DÃte P et al. | [Double blind randomized multicentre study of a seven-day eradication regime of Helicobacter pylori by omeprazole, clarithromycin and ornidazole vs. omeprazole, clarithromycin and metronidazole]. | 2002 | Vnitr Lek | pmid:16737149 |
| Sandri A et al. | Inhibition of Pseudomonas aeruginosa secreted virulence factors reduces lung inflammation in CF mice. | 2018 | Virulence | pmid:29938577 |
| Morgene MF et al. | HaCaT epithelial cells as an innovative novel model of rhinovirus infection and impact of clarithromycin treatment on infection kinetics. | 2018 | Virology | pmid:30077071 |
| Zarogoulidis P et al. | Long-term respiratory follow-up of H1N1 infection. | 2011 | Virol. J. | pmid:21702977 |
| Ebnöther M et al. | Severe bronchiolitis in acute Mycoplasma pneumoniae infection. | 2001 | Virchows Arch. | pmid:11787856 |
| de Mascarel A et al. | Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue. | 2005 | Virchows Arch. | pmid:15742170 |
| Bruhn O et al. | Antimicrobial peptides and proteins of the horse--insights into a well-armed organism. | 2011 | Vet. Res. | pmid:21888650 |
| Clark SE et al. | Identification of a multidrug efflux pump in Flavobacterium johnsoniae. | Vet. Res. | pmid:19558960 | |
| Sieber-Ruckstuhl NS et al. | Long-term cure of disseminated Mycobacterium avium infection in a cat. | 2007 | Vet. Rec. | pmid:17259458 |
| Cattoli G et al. | Helicobacter acinonychis eradication leading to the resolution of gastric lesions in tigers. | 2000 | Vet. Rec. | pmid:10975334 |
| Berghaus LJ et al. | Mutant prevention concentration and mutant selection window for 10 antimicrobial agents against Rhodococcus equi. | 2013 | Vet. Microbiol. | pmid:23915992 |
| Hartmann FA et al. | Molecular characterization of Staphylococcus intermedius carriage by healthy dogs and comparison of antimicrobial susceptibility patterns to isolates from dogs with pyoderma. | 2005 | Vet. Microbiol. | pmid:15917140 |
| Burton AJ et al. | Efficacy of liposomal gentamicin against Rhodococcus equi in a mouse infection model and colocalization with R. equi in equine alveolar macrophages. | 2015 | Vet. Microbiol. | pmid:25666452 |
| Giguère S et al. | In vitro synergy, pharmacodynamics, and postantibiotic effect of 11 antimicrobial agents against Rhodococcus equi. | 2012 | Vet. Microbiol. | pmid:22704561 |
| Hung SW et al. | Antibiotic susceptibility and prevalence of erythromycin ribosomal methylase gene, erm(B) in Streptococcus spp. | 2008 | Vet. J. | pmid:17400007 |
| Sharman MJ et al. | Gastrokine mRNA expression in gastric tissue from dogs with helicobacter colonisation but without inflammatory change during treatment. | 2017 | Vet. Immunol. Immunopathol. | pmid:28494926 |
| Giguère S | Treatment of Infections Caused by Rhodococcus equi. | 2017 | Vet. Clin. North Am. Equine Pract. | pmid:28161038 |
| Muller MG et al. | Acinetobacter baumannii in Localised Cutaneous Mycobacteriosis in Falcons. | 2010 | Vet Med Int | pmid:20871867 |
| Weese JS et al. | Antimicrobial use guidelines for treatment of urinary tract disease in dogs and cats: antimicrobial guidelines working group of the international society for companion animal infectious diseases. | 2011 | Vet Med Int | pmid:21776346 |
| Dhama K et al. | Tuberculosis in Birds: Insights into the Mycobacterium avium Infections. | 2011 | Vet Med Int | pmid:21776352 |
| Rebuelto M and Loza ME | Antibiotic Treatment of Dogs and Cats during Pregnancy. | 2010 | Vet Med Int | pmid:21253497 |
| Murai A et al. | Mastitis caused by Mycobacterium kansasii infection in a dog. | 2013 | Vet Clin Pathol | pmid:23808608 |
| Hylton PK et al. | Intracellular success: cytologic findings in an ulcerated submandibular mass from a cat. | 2006 | Vet Clin Pathol | pmid:16967424 |
| [Experience with treatment of chronic polypoid rhinosinusitis using low doses of clarithromycin in the postoperative period]. | 2012 | Vestn. Otorinolaringol. | pmid:22678641 | |
| Bobacheva TIu | [The treatment of chronic polypous rhinosinusitis in the postoperative period with low doses of clarithromycin]. | 2012 | Vestn. Otorinolaringol. | pmid:23011378 |
| Robinson JG | Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. | 2009 | Vasc Health Risk Manag | pmid:19436666 |
| Kones R | Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. | 2010 | Vasc Health Risk Manag | pmid:20859545 |
| Bronander KA and Bloch MJ | Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data. | 2007 | Vasc Health Risk Manag | pmid:17580728 |
| Wolbrette D et al. | Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy. | 2010 | Vasc Health Risk Manag | pmid:20730068 |
| Falk JA et al. | The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. | 2010 | Vasc Health Risk Manag | pmid:20479949 |
| Edmonds M | The treatment of diabetic foot infections: focus on ertapenem. | 2009 | Vasc Health Risk Manag | pmid:19997576 |
| Laks T et al. | Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: a randomized, open-label, parallel-group, multi-center study: the DISCOVERY-Beta study. | 2008 | Vasc Health Risk Manag | pmid:19337553 |
| Lee CK et al. | Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. | 1999 | Vaccine | pmid:10195786 |
| Rendi-Wagner P et al. | National paediatric immunization program of high risk groups: no effect on the incidence of invasive pneumococcal diseases. | 2009 | Vaccine | pmid:19393711 |